<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01273844</url>
  </required_header>
  <id_info>
    <org_study_id>NJCT-1006</org_study_id>
    <nct_id>NCT01273844</nct_id>
  </id_info>
  <brief_title>Study of Bortezomib +HSCT in Primary Systemic Amyloidosis (AL)</brief_title>
  <official_title>Study of the Combination of Bortezomib and Dexamethasone Followed by HSCT in AL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhi-Hong Liu, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanjing University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of Vel-Dex therapy (bortezomib and dexamethasone)&#xD;
      followed by autologous hematopoietic stem cell transplantation as an initial treatment in&#xD;
      patients with newly diagnosed AL.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive two 21-day cycles of induction therapy with vel / dex regimen.&#xD;
      Bortezomib 1.3mg/m2 on days 1, 4, 8 and 11 will be given by intravenous bolus injection while&#xD;
      Dexamethasone 40 mg/d will be taken orally on days 1-4. After two cycles of vel / dex&#xD;
      therapy, the collection of peripheral blood stem cells (PBSC) should be completed within 4&#xD;
      weeks.Patients will receive ASCT therapy in 8 weeks after collection of PBSC (Recorded as day&#xD;
      0), while melphalan (day -2) with a dose of 100,140 or 200 mg/m2 (choosing a dose according&#xD;
      to the degree of risk for patients ) and Vel 1mg/m2 (days -6, -3, +1, +4) will be given. Four&#xD;
      additional 21-day cycles of Vel treatment (with a dose of 1.6mg/m2 on day 1 and 8 of the&#xD;
      cycle) will be conducted as consolidation therapy during the recommended 60-90 days after&#xD;
      HSCT, or after resumption of hematopoietic function ( neutrophil count &gt; 1.5x109/L and&#xD;
      platelet count&gt; 50x109/L). Later patients won't need maintenance therapy.&#xD;
&#xD;
      The efficacy criteria are the international standards set with consensus of experts in the&#xD;
      Tenth International Symposium on Amyloid and Amyloidosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2011</start_date>
  <completion_date type="Actual">May 12, 2016</completion_date>
  <primary_completion_date type="Actual">May 12, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>12 months</time_frame>
    <description>Complete response rate at 12 months post-transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall response rate</measure>
    <time_frame>12 months</time_frame>
    <description>overall response rate(ie.,CR + PR) at 12 months post-transplantation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>progression-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>progression-free survival (PFS) at 2 years post-transplantation</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Amyloidosis</condition>
  <arm_group>
    <arm_group_label>Bortezomib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive two 21-day cycles of induction therapy with vel / dex regimen. Bortezomib 1.3mg/m2 on days 1, 4, 8 and 11 will be given by intravenous bolus injection while Dexamethasone 40 mg/d will be taken orally on days 1-4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Bortezomib</description>
    <arm_group_label>Bortezomib</arm_group_label>
    <other_name>autologous hematopoietic stem cell transplantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female;&#xD;
&#xD;
          2. aged 18-65 years;&#xD;
&#xD;
          3. Patients with newly diagnosed AL;&#xD;
&#xD;
          4. Appropriate for autologous hematopoietic stem cell transplantation;&#xD;
&#xD;
          5. Abnormal M protein or free light chain detected in serum and / or urine&#xD;
&#xD;
          6. ECOG score 0-2 points;&#xD;
&#xD;
          7. Subjects (or their legal representatives) must signed an informed consent document&#xD;
             indicating understanding the purpose of and procedures required for the study and&#xD;
             willingness to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects received systematic treatment with steroids&#xD;
&#xD;
          2. Subjects received plasmapheresis to treat clinical significant hyperviscosity syndrome&#xD;
             within 4 weeks before enrollment.&#xD;
&#xD;
          3. Pregnant and breastfeeding women;&#xD;
&#xD;
          4. Subjects suffering from multiple myeloma.&#xD;
&#xD;
          5. hypersensitivity to dexamethasone, bortezomib, mannitol, boron, or heparin (if use&#xD;
             catheters);&#xD;
&#xD;
          6. Subjects have severe cardiovascular disease,&#xD;
&#xD;
          7. Subjects have serious physical disease and mental illnesses which may interfere the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>zhihong Liu, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215325</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>January 3, 2011</study_first_submitted>
  <study_first_submitted_qc>January 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2011</study_first_posted>
  <last_update_submitted>April 5, 2017</last_update_submitted>
  <last_update_submitted_qc>April 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing University School of Medicine</investigator_affiliation>
    <investigator_full_name>Zhi-Hong Liu, M.D.</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>hematopoietic stem cell transplantation</keyword>
  <keyword>amyloidosis</keyword>
  <keyword>Bortezomib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

